Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
3.750
-0.020 (-0.53%)
At close: Dec 5, 2025, 4:00 PM EST
3.790
+0.040 (1.07%)
After-hours: Dec 5, 2025, 5:52 PM EST

Lantern Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2018
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2018
Selling, General & Admin
6.636.095.985.835.023.66
Upgrade
Research & Development
13.0416.1311.898.66.572.24
Upgrade
Operating Expenses
19.6722.2217.8814.4311.595.91
Upgrade
Operating Income
-19.67-22.22-17.88-14.43-11.59-5.91
Upgrade
Interest & Investment Income
0.530.740.770.20.07-
Upgrade
Other Non Operating Income (Expenses)
0.40.691.15-0.030.05-
Upgrade
EBT Excluding Unusual Items
-18.75-20.78-15.96-14.26-11.47-5.91
Upgrade
Other Unusual Items
-----0.89-
Upgrade
Pretax Income
-18.92-20.78-15.96-14.26-12.36-5.91
Upgrade
Net Income
-18.92-20.78-15.96-14.26-12.36-5.91
Upgrade
Net Income to Common
-18.92-20.78-15.96-14.26-12.36-5.91
Upgrade
Shares Outstanding (Basic)
11111111114
Upgrade
Shares Outstanding (Diluted)
11111111114
Upgrade
Shares Change (YoY)
0.29%-0.74%-0.08%-0.50%153.31%117.61%
Upgrade
EPS (Basic)
-1.75-1.93-1.47-1.31-1.13-1.37
Upgrade
EPS (Diluted)
-1.75-1.93-1.47-1.31-1.13-1.37
Upgrade
Free Cash Flow
-16.86-17.83-14.37-12.8-10.61-5.67
Upgrade
Free Cash Flow Per Share
-1.56-1.66-1.32-1.18-0.97-1.32
Upgrade
EBITDA
-19.65-22.2-17.86-14.42-11.58-5.9
Upgrade
D&A For EBITDA
0.020.020.010.010.010
Upgrade
EBIT
-19.67-22.22-17.88-14.43-11.59-5.91
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.